Journal Article

Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

Jones, Heather F., Molvi, Zaki, Klatt, Martin G., Scheinberg, David A., Dao, Tao

2021

Overview

The use of T cells reactive with intracellular tumor-associated or tumor-specific antigens has been a promising strategy for cancer immunotherapies in the past three decades, but the approach has been constrained by a limited understanding of the T cell receptor’s (TCR) complex functions and specificities. Newer TCR and T cell-based approaches are in development, including engineered adoptive T cells with enhanced TCR affinities, TCR mimic antibodies, and T cell-redirecting bispecific agents. These new therapeutic modalities are exciting opportunities by which TCR recognition can be further exploited for therapeutic benefit. In this review we summarize the development of TCR-based therapeutic strategies and focus on balancing efficacy and potency versus specificity, and hence, possible toxicity, of these powerful therapeutic modalities.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Amino acids / Animals / Antibodies / Antigen (tumor-associated) / Antigens / Bispecific antibodies / bispecific T cell engager / Cancer immunotherapy / Cancer therapies / cross-reactivity / Humans / immune mobilizing monoclonal T cell receptors against cancer / Immunology / Immunotherapy / Ligands / Lymphocytes / Lymphocytes T / Mass spectrometry / Mutation / peptide- major histocompatibility complexes / Peptides / Proteins / Receptors, Antigen, T-Cell - immunology / Scientific imaging / T cell receptor / T cell receptors / Toxicity / tumor infiltrating lymphocytes / Tumors